Literature DB >> 9240552

Patient dose due to colon examination: dose assessment and results from a survey in The Netherlands.

J Geleijns1, J J Broerse, M P Shaw, F W Schultz, W Teeuwisse, J G van Unnik, J Zoetelief.   

Abstract

PURPOSE: To determine the effective dose to the patient during radiographic colon examination.
MATERIALS AND METHODS: The integral dose-area product was measured during colon examination in 1,733 patients aged 18-94 years. The effective dose was estimated from the dose-area product through computer simulations of radiation transport in anthropomorphic phantoms. The relation between patient dose and imaging or radiographic technique was considered. Patient dose from a biphasic colon examination was compared to that from a double-contrast examination.
RESULTS: The factors for converting dose-area product to effective dose were 0.29 mSv x Gy(-1) x cm(-2) and 0.27 mSv x Gy(-1) x cm(-2) for the biphasic and the double-contrast studies, respectively. The average dose-area product for the biphasic colon examination was 21 Gy x cm2, of which 13 Gy x cm2 was attributed to the double-contrast views. The average dose-area product was 29 Gy x cm2 (range, 18-53 Gy x cm2); the average effective dose was 4.7 mSv (range, 2.7-8.4 mSv).
CONCLUSION: Careful selection of the radiologic technique resulted in a surprisingly low dose during the biphasic colon examination. It is recommended that additional filtration of at least 0.1-mm copper be applied and that a screen-film combination with a speed class of at least 400 be used. Dose reduction when using digital techniques is often not realized in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9240552     DOI: 10.1148/radiology.204.2.9240552

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  1 in total

1.  An inter-hospital comparison of patient dose based on clinical indications.

Authors:  W Teeuwisse; J Geleijns; W Veldkamp
Journal:  Eur Radiol       Date:  2006-10-24       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.